相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial
Daniel Dive et al.
CHEMMEDCHEM (2008)
Synthesis of cycloruthenated compounds as potential anticancer agents
Lida Leyva et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2007)
Ferrocifens and ferrocifenols as new potential weapons against breast cancer
Anh Nguyen et al.
CHIMIA (2007)
The presence of a ferrocenyl unit on an estrogenic molecule is not always sufficient to generate in vitro cytotoxicity
Anne Vessieres et al.
CHEMMEDCHEM (2006)
Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy
Wee Han Ang et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2006)
Metal complex SERMs (selective oestrogen receptor modulators).: The influence of different metal units on breast cancer cell antiproliferative effects
A Vessières et al.
DALTON TRANSACTIONS (2006)
Synthesis of novel ferrocenyl oxindole and ferrocene substituted dispiroheterocycles through [3+2]cycloaddition of azomethine ylides
J Jayashankaran et al.
SYNTHETIC COMMUNICATIONS (2006)
New principles in medicinal organometallic chemistry
U Schatzschneider et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates
E Hillard et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Ruthenium half-sandwich complexes bound to protein kinase Pim-1
JE Debreczeni et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Mammalian late vacuole protein sorting orthologues participate in early endosomal fusion and interact with the cytoskeleton
SCW Richardson et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Bioorganometallic chemistry of ferrocene
DR van Staveren et al.
CHEMICAL REVIEWS (2004)
Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens:: Evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines
S Top et al.
CHEMISTRY-A EUROPEAN JOURNAL (2003)
Protein kinase inhibitors as a therapeutic modality
A Levitzki
ACCOUNTS OF CHEMICAL RESEARCH (2003)
SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling
RA Blake et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation
DQ Guo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
